A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV‐E) or teniposide (CAV‐T), followed by recombinant interferon‐α maintenance therapy or observation, in small cell lung carcinoma patients with complete responses

Studies of chemotherapy for patients with small cell lung carcinoma (SCLC) have shown that teniposide (T) may have higher activity than etoposide (E). In this randomized, controlled Phase III study, the authors compared cyclophosphamide, doxorubicin, and vincristine (CAV) with E and CAV with T as induction treatments for patients with SCLC. A second objective of the study was to study patients who had achieved complete response (CR). They were considered for a second randomization to maintenance therapy, in which they would receive either recombinant interferon‐α (rIFN‐α) or no treatment.

[1]  T E Walsh,et al.  Reporting results. , 1969, Archives of otolaryngology.

[2]  A. Pack,et al.  Intensive-coronary-care units. , 1970, Lancet.

[3]  M. Bychkov,et al.  [Chemotherapy of lung cancer]. , 1972, Voprosy onkologii.

[4]  S. George,et al.  Planning the size and duration of a clinical trial studying the time to some critical event. , 1974, Journal of chronic diseases.

[5]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[6]  I. Tannock,et al.  Criteria of tumor response used in clinical trials of chemotherapy. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Hansen,et al.  Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  N. Miyazawa,et al.  In vitro antitumor activity of teniposide against carcinoma of the lung in human tumor clonogenic assay. , 1986, Anticancer research.

[9]  M. Broggini,et al.  Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse. , 1986, European journal of cancer & clinical oncology.

[10]  F. Balkwill,et al.  INTERFERONS IN CANCER THERAPY: A REAPPRAISAL , 1987, The Lancet.

[11]  R. Joss,et al.  Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC). , 1988, European journal of cancer & clinical oncology.

[12]  L. Case,et al.  Improvement of long-term survival in extensive small-cell lung cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G Bonardi,et al.  Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Ihde,et al.  Therapy of small cell lung cancer: a perspective on two decades of clinical research. , 1988, Seminars in oncology.

[15]  J. Abrams,et al.  Staging, prognostic factors, and special considerations in small cell lung cancer. , 1988, Seminars in oncology.

[16]  W. Hong,et al.  Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Dazzi,et al.  Teniposide (VM26) as second-line treatment for small cell lung cancer. , 1990, Anticancer research.

[18]  L. Einhorn,et al.  Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. , 1990, Seminars in oncology.

[19]  T. Therneau,et al.  Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Hansen,et al.  Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Cellerino,et al.  Teniposide as single drug therapy for elderly patients affected by small cell lung cancer. , 1992, European journal of cancer.

[22]  D. Ihde,et al.  Chemotherapy of Lung Cancer , 1992 .

[23]  P. Clark,et al.  The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer. , 1992, Seminars in oncology.

[24]  K. Cantell,et al.  Natural interferon alfa as maintenance therapy for small cell lung cancer. , 1992, European journal of cancer.

[25]  J. Jett,et al.  Immune response induced in small-cell lung cancer by maintenance therapy with interferon gamma. , 1993, Journal of the National Cancer Institute.

[26]  J. Jett,et al.  Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Gasparini,et al.  Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy. , 1994, Anticancer research.

[28]  J. Herndon,et al.  A Phase II Study of Recombinant Interferon‐Gamma Following Combination Chemotherapy for Patients with Extensive Small Cell Lung Cancer , 1995, American journal of clinical oncology.

[29]  J. Crowley,et al.  Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  G. Giaccone,et al.  Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. , 1997, European journal of cancer.